The Lancet Just Retracted a 49-Year-Old Editorial That Johnson & Johnson Used for Decades to Say Talc Was Safe — Here Is What It Means for Your Case
If you are reading this at 2 a.m. because you or someone you love used talcum powder for years and then heard the word cancer — ovarian cancer, mesothelioma, a diagnosis that came out of nowhere and turned everything sideways — you already know the feeling. You trusted a product. You used it the way it was packaged to be used. Nobody warned you. And now you are finding out that the science saying it was safe may have been shaped, behind closed doors, by the company selling it.
That is exactly what The Lancet — one of the oldest and most respected medical journals in the world — confirmed in March 2026, when it retracted a 49-year-old unsigned editorial that had argued against government testing for asbestos in cosmetic talc. The journal’s editors concluded that the author, a cancer researcher named Francis J.C. Roe, had an undisclosed financial relationship with Johnson & Johnson, that he shared a draft of the article with a J&J executive before publication, and that he incorporated the company’s feedback into the text. Had the editors known at the time, they wrote, they would never have published it.
That editorial has been cited for decades by corporate defense attorneys to argue that the medical establishment did not consider asbestos in talc to be dangerous. Now it is retracted. Now it is an artifact of what appears to be corporate influence on the scientific record — and if you have a talc case, or have been wondering whether you have one, that changes the landscape.
We handle toxic tort and product liability cases for people across the country who were harmed by products they were told were safe. Ralph Manginello has spent 27+ years in courtrooms, including federal court. Lupe Peña spent years inside a national insurance-defense firm before joining this side of the table. We are writing this for you — the person who just found out the science was not as independent as everyone was told.
What The Lancet Retracted and Why It Matters
The editorial was published in 1977, unsigned — which was standard practice for journal commentaries at the time. It argued against government-mandated regulatory testing for asbestos in cosmetic talc. At that moment, the U.S. Food and Drug Administration was considering exactly that kind of monitoring. The FDA ultimately left asbestos testing in the hands of cosmetics companies themselves. The editorial became part of the scientific record that defense lawyers pointed to when they told juries the medical field did not consider asbestos-contaminated talc to be a health risk.
Public health historians David Rosner and Gerald Markowitz — who have served as expert witnesses on behalf of people who developed diseases after exposure to asbestos products, including talc — discovered through years of litigation document discovery that the anonymous author was Francis J.C. Roe. Roe, who died in 2007, worked as an independent consultant but had financial ties to J&J. In a 1979 letter published in The Lancet, Roe himself disclosed that he was a consultant to the Cosmetic Toiletry and Perfumery Association — but he never disclosed his J&J relationship in connection with the 1977 editorial.
The deeper problem is the paper trail. In a 1977 letter to Gavin Hildick-Smith, then the director of medical affairs at Johnson & Johnson, Roe wrote:
“I have taken into account your two points on the original … in a slightly different way from that proposed by yourself – But I think I have met your two points.”
Rosner and Markowitz say this indicates Roe shared the article with J&J and sought the company’s input before it was published. The Lancet’s editors agreed. In their retraction statement, they wrote:
“Roe’s conflict of interest with Johnson & Johnson was a clear breach of publishing ethics. In our view, had the editors at the time known of this situation and been aware of the author’s undeclared competing interest, they would not have published this commentary.”
For a talc plaintiff, this retraction does something concrete: it removes a defense tool that has been used for years. Every defense expert who previously cited or relied on the 1977 commentary now faces cross-examination about the credibility of their scientific basis. The editorial that was once cited as proof that “the medical field did not consider asbestos in talc dangerous” is now, on the record, a piece of literature shaped by the very company whose product was at issue.
Johnson & Johnson: The Defendant and Its Corporate Structure
Johnson & Johnson is the parent corporation and the manufacturer facing more than 67,000 plaintiffs who claim its talc products caused their cancer. The bulk of those cases involve ovarian cancer claims from women who used talc-based body powder for genital hygiene over years or decades. A significant subset involves mesothelioma — a cancer of the lining of the lungs or abdomen that is essentially specific to asbestos exposure — from people who inhaled asbestos-contaminated talc.
J&J is what we call a tier-mega defendant. It is one of the largest pharmaceutical and consumer-product companies in the world. It is largely self-insured, meaning it pays claims out of its own treasury through layered self-insured retention and excess coverage towers — not a small policy with a traditional carrier. When you are dealing with a company this size, the coverage architecture is a tower: the company’s own money sits on the first layers, and excess insurers sit above. That means the company fights hard on every claim because every dollar comes off its own books.
The corporate structure matters because J&J has used it to try to wall off its talc liability. In 2021, J&J created LTL Management LLC to take on its talc-related liabilities, and later formed Red River Talc LLC for the same purpose. Through these subsidiaries, the parent company filed for bankruptcy three times — attempting to channel all talc claims into a structured settlement through the bankruptcy court rather than facing juries in the tort system.
All three attempts failed. The last bankruptcy attempt was dismissed on March 31, 2025, by the U.S. Bankruptcy Court for the Southern District of Texas, which found vote-solicitation irregularities and impermissible nonconsensual third-party releases. After that dismissal, J&J announced it would not appeal and instead “return to the tort system to litigate and defeat these meritless talc claims” — which, translated from corporate-speak, means the cases are going back to courthouses across the country.
The creation of LTL Management and Red River Talc, followed by three rejected bankruptcy filings, supports a theory that lawyers call alter-ego or veil-piercing — the argument that these subsidiaries were not real independent companies but were created specifically to shield the parent from liability. Where a court agrees, it can hold the parent corporation directly responsible for talc-related injuries, bypassing the subsidiary structure entirely.
Asbestos, Talc, and Cancer: The Science in Plain Language
Talc and asbestos are minerals that are often found in the same geological formations. They are mined from the same earth. When talc is mined, it can be contaminated with asbestos fibers — and for decades, testing of cosmetic talc products has detected asbestos in some samples.
The mechanism of harm depends on the type of cancer:
Mesothelioma is a cancer of the thin membrane that lines the lungs, abdomen, and other internal organs. It is essentially specific to asbestos exposure — meaning when a person develops mesothelioma, the disease itself points back to asbestos as the cause, even decades later. Inhaled asbestos fibers lodge in the lining of the lungs or abdomen. The body cannot clear them. Over decades of chronic irritation and cellular damage, malignant transformation occurs. The latency period — the time from first exposure to diagnosis — is typically 20 to 50 years, most often 30 to 40 years. A person exposed to asbestos-contaminated talc in their twenties or thirties may not be diagnosed until they are in their sixties or seventies.
Ovarian cancer has been linked to the long-term genital application of talc-based body powder. The proposed mechanism is that talc particles — potentially contaminated with asbestos — travel through the reproductive tract to the ovaries, where chronic inflammation and cellular damage may contribute to malignant transformation over years or decades. The causal link between talc use and ovarian cancer is more contested than the asbestos-mesothelioma link, which is where the scientific literature — including the now-retracted Lancet editorial — becomes the battleground.
This is why the Lancet retraction matters so much. The 1977 editorial argued against requiring the very testing that would have detected asbestos contamination in cosmetic talc. If that testing had been mandated, contaminated products might have been kept off store shelves. The editorial was part of the scientific record that defense lawyers cited to say the risk was not established. And now we know the author was a paid consultant to the company selling the product, sharing drafts with a J&J executive before publication.
The Regulatory Failure: How the FDA Testing Rule Was Withdrawn
The regulatory backstory makes the Lancet retraction even more significant. Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the FDA gained new authority over cosmetic products. In 2024, the FDA proposed a new rule that would have required manufacturers to use two different laboratory techniques to test for the presence of asbestos in cosmetics containing talc. This would have been a major step toward closing the regulatory gap that has existed since 1977 — the same gap the retracted Lancet editorial argued should remain open.
Then, on November 28, 2025, the FDA withdrew the proposed rule. The agency’s announcement stated:
“Good cause exists to withdraw the proposed rule at this time. We are withdrawing the proposed rule to reconsider best means of addressing the issues.”
Experts characterized the withdrawal as “enormously valuable” for Johnson & Johnson and suspected it “smacks of industry influence.” The timing is striking: the FDA pulled the rule, and less than two weeks later, on December 8, 2025, Rosner and Markowitz reached out to The Lancet with the documents revealing Roe’s undisclosed J&J ties. The retraction and the rule withdrawal happened within weeks of each other — one closing a door on regulatory oversight, the other opening a window into how the science was shaped.
For litigation purposes, the FDA’s withdrawal of the asbestos testing rule is significant because it documents the regulatory gap that allowed manufacturers to self-police asbestos contamination. The absence of mandatory testing meant contaminated products could reach consumers without detection — and the 1977 Lancet editorial argued precisely against imposing the regulatory oversight that might have prevented that exposure.
The Evidence: What Exists, Who Holds It, and What Is at Risk
In a talc case, the evidence falls into several categories, each with its own preservation timeline:
The Lancet retraction and supplemental documents — The retraction notice, the Rosner-Markowitz letter, the Roe-Hildick-Smith correspondence, and the editors’ reply are all published in The Lancet and permanently preserved in the journal record. This evidence does not decay. It is now part of the permanent scientific and legal record, available to every plaintiff in the talc litigation.
The Rosner-Markowitz discovery archive — These two researchers have amassed millions of documents collected during discovery processes in talc and asbestos litigation. These archives contain internal J&J communications about talc safety, asbestos testing results, and scientific publication strategy. They may reveal additional undisclosed influence operations beyond the Roe editorial. However, these documents are subject to protective orders and retention policies, and corporate reorganizations and subsidiary wind-downs create destruction risk. If you have a case, the discovery process is how we access this material — but we have to move before it is gone.
J&J internal talc testing records and safety correspondence from the 1970s forward — These are critical for proving actual knowledge of asbestos contamination and for establishing the predicate for punitive damages. Internal corporate testing that detected asbestos in talc, followed by a decision not to warn consumers, is the kind of evidence that turns a failure-to-warn case into a punitive-damages case. These records are at risk through corporate document destruction schedules, subsidiary bankruptcies, and personnel transitions. When a company has been ordered to preserve evidence through a litigation hold, destruction becomes spoliation — but only if the hold was in place before the records disappeared.
FDA rulemaking docket records (2024-2025) — The administrative record from the proposed asbestos testing rule, including comment submissions and the withdrawal rationale, documents the regulatory gap and may reveal industry influence on the withdrawal. These are available through federal records requests and do not face immediate decay, but political transitions may affect accessibility.
Defense expert witness filings citing the 1977 Lancet commentary — Every court filing in which a defense expert cited or relied upon the retracted editorial is preserved in the court record. These filings provide impeachment material for cross-examination — we can show the jury that the expert relied on a paper that was retracted because its author had an undisclosed financial conflict with the defendant.
The urgency here is real. If you are sitting on a potential talc claim, the documents that could prove what J&J knew and when are aging. Corporate document retention schedules do not wait for lawsuits. Subsidiary bankruptcies create gaps in the corporate memory. The preservation letter — the formal demand that a company freeze all relevant evidence — is one of the first things that goes out the day you call a lawyer. Not after the case is filed. Not after you gather your medical records. The day you call.
The Corporate Defense Playbook: What J&J Will Do and How We Counter It
Johnson & Johnson has been defending these cases for over a decade and has developed a sophisticated playbook. If you are a plaintiff, you need to know what is coming.
Play 1: “The retraction is a litigation tactic, not science.” J&J’s representatives have already characterized the retraction as “part of ongoing and underhanded litigation tactics” by plaintiffs’ lawyers seeking to “breathe new life into a tall tale.” The counter is simple: the retraction was issued by The Lancet’s own editors, not by plaintiffs’ lawyers. The journal’s editors independently concluded that the undisclosed conflict of interest was a “clear breach of publishing ethics.” The evidence — Roe’s letter to Hildick-Smith sharing the draft and incorporating feedback — is J&J’s own correspondence. This is not a lawyer’s opinion. It is the company’s own paper trail.
Play 2: “The editorial was unsigned and 50 years old — nobody relied on it.” One defense attorney downplayed the editorial’s significance, saying it “would not be relied upon to any significant degree” because it was old and unsigned. The counter: Rosner and Markowitz reported being “confronted by attorneys for talc products” with the editorial four or five times in the last few years. If defense lawyers were still citing it as recently as the past few years, it was still in use as a defense tool. And the retraction eliminates that tool going forward.
Play 3: “Talc does not contain asbestos — you are confusing talc with talcum powder products.” This is a technical distinction the defense draws between raw talc mineral and the consumer products that contain it. The counter: the issue has never been whether pure talc contains asbestos. The issue is whether cosmetic talc products — the ones consumers actually bought and used — were contaminated with asbestos during mining and processing. Internal testing and government testing have detected asbestos in cosmetic talc products. The retracted 1977 editorial itself argued against mandating the testing that would have detected this contamination.
Play 4: The statute of limitations attack. J&J will argue that you waited too long to file. The counter is the discovery rule — a legal doctrine that most states apply to toxic exposure cases. Under the discovery rule, the clock to file a lawsuit generally does not start on the date you were exposed to the product. It starts when you discovered, or by reasonable diligence should have discovered, that your injury was connected to the exposure. For a woman who used talc powder for thirty years and was diagnosed with ovarian cancer in 2023, the clock may have started on the date of diagnosis — or on the date she first learned that talc use had been linked to ovarian cancer. Every state’s rule is different, and some states have outer deadlines called statutes of repose that can cut off a claim even before discovery. This is why confirming the deadline in your specific state is urgent — not next month, not after you feel better, now.
Play 5: The bankruptcy maneuver. J&J created LTL Management and Red River Talc to channel liability through bankruptcy — three times. Each time, courts rejected the attempt. After the third failure, J&J announced it would “return to the tort system.” The counter to any future restructuring attempt is the alter-ego theory: these subsidiaries were not independent companies. They were created by the parent, funded by the parent, and designed to shield the parent from jury verdicts. Courts have seen through this, and we expect them to continue seeing through it.
What Your Talc Case Is Worth
Talc case values range widely based on the type of cancer, the strength of product-specific exposure evidence, the jurisdiction where the case is filed, and the degree to which corporate misconduct can be proven.
Mesothelioma cases typically command higher values than ovarian cancer cases because the causal pathway is clearer — mesothelioma is essentially specific to asbestos, and asbestos has been detected in cosmetic talc products. A mesothelioma case with strong product-identification evidence, compelling punitive evidence of corporate knowledge, and a favorable venue can reach into the tens of millions of dollars. The reported 2025 California mesothelioma verdict — $966 million for the family of a woman who died from mesothelioma linked to cosmetic talc — is an example of what a strong mesothelioma case can produce, though that verdict’s appellate status should be confirmed at the time you are reading this.
Ovarian cancer cases represent the bulk of the 67,000+ claims. The causal link between genital talc use and ovarian cancer is more contested, which means case values depend heavily on the strength of the exposure evidence (how long you used the product, how frequently, which brand) and the jurisdiction. Individual ovarian cancer case resolutions can range from several hundred thousand dollars to multiple millions, with outlier verdicts reaching far higher.
Punitive damages are a central feature of talc verdicts. The reported verdicts illustrate the scale: a 2018 Missouri jury verdict of $4.69 billion against J&J was reduced on appeal to approximately $2.1 billion — and the U.S. Supreme Court declined to review that reduction in June 2021, meaning the $2.1 billion figure stands as final. That is not a press release number. It is a number the highest court in the country let stand. More recently, a 2025 Maryland verdict of $1.5 billion was reported for a single ovarian cancer plaintiff. These figures represent cases with strong causation evidence, compelling punitive evidence, and favorable venues — they are not typical outcomes, but they show what the ceiling looks like when the evidence is strong and the jury is outraged.
The Lancet retraction and the newly available correspondence between Roe and Hildick-Smith may enhance punitive damage arguments across the entire docket. Evidence that a company reviewed and influenced a supposedly independent scientific publication without disclosure is exactly the kind of conduct that juries punish — and the retraction gives that evidence the imprimatur of one of the world’s most respected medical journals.
Past results depend on the facts of each case and do not guarantee future outcomes. What we can tell you honestly is that the evidence landscape just shifted in favor of plaintiffs, and cases that may have seemed difficult to prove a year ago now have a new evidentiary foundation.
The Proof Story: How a Talc Case Is Actually Built
Here is how a talc case is assembled, from the first phone call through trial:
Week one: The preservation letter goes out. Before anything else, we send a formal litigation-hold letter to Johnson & Johnson and any relevant subsidiaries, ordering them to preserve all documents related to talc testing, asbestos contamination, safety communications, and scientific publication strategy. This letter is what converts routine document destruction into spoliation — if they destroy evidence after receiving it, the jury can be told to assume the worst about what was lost.
Intake and exposure documentation. We work with you to build a complete picture of your talc use: which products, which brands, how often, over what period, and for what purpose. Receipts, old purchase records, photographs of product containers, witness statements from family members who can corroborate your long-term use. For mesothelioma cases, we trace every possible source of asbestos exposure — not just talc — because the defense will argue your cancer came from somewhere else. For ovarian cancer cases, the exposure history is the foundation of the causation case.
Medical records and expert review. We pull your complete medical history — diagnosis, pathology reports, treatment records, prognosis. Board-certified oncologists and pathologists review your case to confirm the diagnosis and connect it to talc exposure. For mesothelioma, the pathology itself is near-conclusive of asbestos exposure. For ovarian cancer, the causal link is built through epidemiological evidence, exposure history, and expert testimony.
Discovery: the document war. In litigation, we demand J&J’s internal communications about talc safety, asbestos testing results, and scientific publication strategy. The Rosner-Markowitz archive — millions of documents collected through years of litigation — is a resource that may contain evidence of additional undisclosed influence operations. We also demand all communications referencing the Roe editorial, the Lancet retraction, and any other publications where J&J may have had undisclosed editorial input.
Expert witnesses in public health history and publishing ethics. The retraction opens a new evidentiary lane. Experts who can testify about the history of corporate influence on scientific literature — and about the specific breach of publishing ethics that The Lancet identified — can contextualize the Roe editorial within a pattern of what appears to be corporate manipulation of the scientific record.
Depositions. J&J executives, scientific consultants, and corporate representatives are questioned under oath about what they knew about asbestos in talc, when they knew it, and what they did or did not do to warn consumers. The Roe-Hildick-Smith correspondence is a deposition exhibit — we put it in front of the witness and ask them to explain why a J&J executive was reviewing and commenting on a supposedly independent scientific editorial.
The FDA administrative record. Through Freedom of Information Act requests and administrative record discovery, we investigate whether industry communications influenced the FDA’s November 2025 withdrawal of the asbestos testing rule. If there is a paper trail between J&J and the FDA’s decision to pull the rule, that is evidence of ongoing corporate influence — not just a historical problem from 1977, but a current one.
The number at the end. The demand or verdict is built from all of it — your medical costs, your lost wages and diminished earning capacity, your pain and suffering, the loss of the life you expected to live, and where the evidence supports it, punitive damages designed to punish the company for conscious disregard of consumer safety. A life-care planner builds the cost of future treatment. A forensic economist reduces it to present value. The adjuster’s first offer is a fraction of that number. Our job is to make sure the number reflects the full measure of the loss.
Your First Steps: What to Do Now
If you or a loved one used talc products and were later diagnosed with ovarian cancer or mesothelioma, here is what we need you to do — and what we need you not to do.
Do document your product use history. Write down everything you can remember: which brand or brands of talc powder you used, how often, for how many years, and for what purpose. If you still have product containers, bottles, or packaging, photograph them and keep them — do not throw them away. If family members or friends can corroborate your long-term use, note their names. The exposure history is the foundation of the case.
Do gather your medical records. You need your diagnosis, pathology reports, treatment records, and the date you first learned your cancer might be connected to talc use. That date — the date you connected the disease to the exposure — is potentially the day the statute of limitations clock started, not the date you were exposed. The discovery rule may protect you if you only recently learned of the connection, but every state’s rule is different and the deadline in your state is a hard gate that can kill the case if missed.
Do call us. The consultation is free. The call is confidential. We do not get paid unless we win your case. We work on contingency — 33.33% before trial, 40% if the case goes to trial. You can reach us at 1-888-ATTY-911, 24 hours a day, 7 days a week. You will speak to a live person, not an answering service.
Do not discuss your case publicly. Do not post about it on social media. Do not contact Johnson & Johnson directly. Defense counsel monitor these channels for inconsistent statements, and a single post can be taken out of context and used against you.
Do not sign anything from any insurance company or claims administrator. If you receive a communication from J&J, from LTL Management, from Red River Talc, or from any entity offering a settlement or asking you to sign a release, do not sign it without speaking to a lawyer first. The quick settlement check that arrives before you understand the full value of your case is designed to close the file cheaply — not to make you whole.
Do not wait. The statute of limitations in your state is a hard deadline. The evidence is aging. The preservation letter needs to go out before documents are destroyed. If you are reading this and wondering whether it is too late, the safest thing to do is call and ask — the answer may surprise you, especially if the discovery rule applies and you only recently connected your diagnosis to talc use.
Who We Are
Ralph Manginello is our Managing Partner — 27+ years licensed, admitted in Texas and to the U.S. District Court for the Southern District of Texas, including the Bankruptcy Court. He was a journalist before he was a lawyer, which means he knows how to find the story the documents tell. He has spent his career in courtrooms, including federal court, and he does not like losing. Read more about Ralph here.
Lupe Peña is our Associate Attorney — 13+ years licensed, admitted in Texas and to the U.S. District Court for the Southern District of Texas. Before he joined this side of the table, Lupe spent years inside a national insurance-defense firm. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how claim valuation works from the inside — how reserves are set, how IME doctors are selected, how surveillance is deployed, and how delay tactics are engineered. Now he uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full consultations in Spanish without an interpreter. Read more about Lupe here.
We handle wrongful death and catastrophic injury cases alongside our toxic tort and product liability practice. The Manginello Law Firm, PLLC — operating as Attorney911 — has been in business since July 18, 2001. We have recovered more than $50 million for our clients. We have a 4.9-star Google rating from more than 251 reviews. Our emergency hotline is staffed 24/7 by live people, not an answering service.
If you or a loved one developed cancer after using talc products, contact us today or call 1-888-ATTY-911. The consultation is free. The call is confidential. We do not get paid unless we win your case.
Hablamos Español. Lupe Peña conducts full consultations in Spanish — without an interpreter, without a language barrier, without anything lost in translation. If your family communicates in Spanish, we serve you fully in your language.
Frequently Asked Questions
What does the Lancet retraction mean for my talc case?
The retraction removes a defense tool that has been used for years. The 1977 editorial was cited by corporate defense attorneys to argue that the medical field did not consider asbestos in talc dangerous. Now that the editorial has been retracted because its author had an undisclosed financial relationship with Johnson & Johnson — and shared a draft with a J&J executive before publication — defense experts who previously relied on it face cross-examination about the credibility of their scientific basis. The retraction also provides new evidence supporting punitive damages claims, because it documents corporate influence on the scientific record.
I used talc powder for years and was diagnosed with ovarian cancer. Do I have a case?
You may. The strength of your case depends on several factors: how long you used talc products, which brands, how frequently, whether you have medical records establishing your diagnosis and treatment, and the statute of limitations in your state. More than 67,000 plaintiffs have filed claims against J&J alleging that talc products caused their ovarian cancer. The Lancet retraction strengthens the evidentiary foundation for these claims. We need to review your specific exposure history and medical records to give you an honest assessment — that is what the free consultation is for.
How long do I have to file a talc lawsuit?
The deadline depends on your state’s statute of limitations, which varies across jurisdictions — typically ranging from two to six years for personal injury claims and one to three years for wrongful death claims. However, most states apply a discovery rule for toxic exposure cases: the clock generally starts when you discovered, or by reasonable diligence should have discovered, that your injury was connected to the product. For many talc plaintiffs, that date may be the date of their cancer diagnosis — or the date they first learned that talc use had been linked to cancer. Some states also have statutes of repose that can impose an outer deadline regardless of discovery. J&J’s three failed bankruptcy attempts may have tolled or paused limitation periods in certain cases. We need to confirm the specific deadline in your state — and we need to do it quickly, because the clock is a hard gate that can end the case if missed.
What if my loved one died from cancer and I think talc caused it?
You may have a wrongful death claim, a survival claim, or both — depending on your state’s law. Wrongful death claims are brought by surviving family members for the losses they suffered: lost financial support, lost companionship, the value of the life that was taken. Survival claims are brought by the estate for the victim’s pain and suffering between injury and death, plus pre-death medical expenses. The exact beneficiaries who can recover, and what damages each type of claim allows, vary by state. If your loved one used talc products for years and was diagnosed with ovarian cancer or mesothelioma, call us — we can evaluate whether a claim is still viable under your state’s wrongful death statute of limitations.
What is the difference between ovarian cancer claims and mesothelioma claims in talc litigation?
Mesothelioma is a cancer of the lining of the lungs or abdomen that is essentially specific to asbestos exposure — meaning the disease itself is near-conclusive proof of asbestos exposure. Mesothelioma claims in talc litigation argue that asbestos-contaminated talc was the source of the exposure. These cases typically command higher values because the causal pathway is clearer. Ovarian cancer claims argue that long-term genital application of talc products caused or contributed to the development of ovarian cancer. The causal link is more contested, which means these cases depend more heavily on exposure history, epidemiological evidence, and expert testimony. Both types of claims are part of the more than 67,000 cases pending against J&J.
Did Johnson & Johnson know about asbestos in its talc products?
Internal corporate documents produced in litigation — including documents in the Rosner-Markowitz archive of millions of pages — have been reported to contain evidence that J&J’s own testing detected asbestos in its talc products over a period of decades. The 1977 Lancet editorial that was retracted argued against requiring the government testing that would have mandated detection and disclosure. The Roe-Hildick-Smith correspondence shows that a J&J executive reviewed and commented on that editorial before publication. Whether J&J had specific knowledge of asbestos contamination in its specific products, and when, is a question that is litigated through discovery — and the preservation of those internal documents is one of the reasons we send a litigation-hold letter immediately.
What if I think it is too late to file a claim?
Many people assume that because their talc use was decades ago, or because their diagnosis was years ago, they have missed the deadline. That is often wrong. The discovery rule — which most states apply to toxic exposure cases — generally starts the clock when you discovered, or should have discovered, the connection between your disease and the product. If you were diagnosed with ovarian cancer five years ago but only learned last year that talc use had been linked to ovarian cancer, the clock in your state may have started last year, not five years ago. Additionally, J&J’s three bankruptcy filings may have paused limitation periods in certain jurisdictions. The only way to know for certain is to call and ask — we will confirm the deadline in your state, and if the door is still open, we will move to preserve evidence immediately.
How much does it cost to hire a talc lawyer?
Nothing upfront. We work on contingency — we do not get paid unless we win your case. Our fee is 33.33% of the recovery before trial and 40% if the case goes to trial. The consultation is free. The call is confidential. You can reach us at 1-888-ATTY-911, 24 hours a day, 7 days a week. You will speak to a live person, not an answering service.
What should I do to preserve evidence of my talc use?
Write down everything you remember about your talc use: the brand or brands, how often you used the product, over what period of years, and for what purpose. If you still have product containers, bottles, or packaging, photograph them and keep them — do not discard them. If family members or friends can corroborate your long-term use, note their names and what they know. Gather your medical records: diagnosis, pathology reports, treatment history, prognosis. Do not post about your case on social media. Do not contact Johnson & Johnson directly. Do not sign anything from any entity offering a settlement without speaking to a lawyer first. Then call us — the preservation letter to J&J goes out the day you become our client.
Can I still file a claim if J&J tried to use bankruptcy to resolve talc cases?
Yes. All three of J&J’s bankruptcy attempts — through LTL Management and Red River Talc LLC — were rejected by the courts. The last attempt was dismissed on March 31, 2025. J&J subsequently announced it would return to the tort system. That means cases are going back to courthouses across the country. The bankruptcy filings may have tolled or paused limitation periods in certain cases, which could actually help you if you were worried about the deadline. The corporate structure — LTL Management, Red River Talc, the parent J&J — is part of the case, and we evaluate alter-ego and veil-piercing theories to hold the parent directly liable.
Is the talc litigation still active?
Yes. As of mid-2026, more than 67,000 plaintiffs have claims pending against J&J. The federal multidistrict litigation — MDL-2738, In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation — has more than 68,000 actions pending in the District of New Jersey. J&J’s three bankruptcy attempts failed, and the company has returned to the tort system. Recent verdicts include a $1.5 billion award in Maryland in 2025 and a $966 million verdict in California in 2025 for a mesothelioma death. The Lancet retraction and the FDA’s withdrawal of the proposed asbestos testing rule are the most recent developments, and both have significant implications for pending and future cases. The litigation is not winding down — it is entering a new phase.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Every case is different. Contacting the firm is free and confidential. If you or a loved one developed cancer after using talc products, call 1-888-ATTY-911. We do not get paid unless we win your case.
The Manginello Law Firm, PLLC — Attorney911 — Legal Emergency Lawyers™
1177 West Loop S, Suite 1600, Houston, TX 77027
1-888-ATTY-911 (1-888-288-9911) — 24/7 live staff — Free consultation — No fee unless we win.
Hablamos Español.